Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed

We read with great interest the article by Murakami et al,1 who performed a randomised, double-blinded study of vonoprazan-based Helicobacter pylori (H. pylori) eradication therapy. They showed high success rates for vonoprazan-based first-line and second-line H. pylori treatments, with eradication rates of 92.6% and 98%, respectively. However, the study populations of second-line therapy included patients for whom both lansoprazole-based and vonoprazan-based first-line treatments failed, and those for whom vonoprazan-based first-line therapy failed numbered only 14. In terms of second-line therapy, we think that the eradication rate in patients for whom vonoprazan-based first-line therapy failed is more important. We conducted a multicenter cohort study of vonoprazan-based second-line therapy among patients for whom vonoprazan-based first-line treatment failed. Primary end points were eradication rates and adverse events in first-line and second-line treatments. First-line and second-line H. pylori eradication rates were 90.6% (95% CI 86.3% to 93.9%) and 87.0% (95% CI...

Source: Gut - March 10, 2017 Category: Gastroenterology Authors: Katayama, Y., Toyoda, K., Kusano, Y., Suda, T., Adachi, S., Terauchi, I., Oka, S., Takahashi, M., Tamano, M. Tags: PostScript Source Type: research